128 related articles for article (PubMed ID: 20874646)
1. Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker.
Poirier N; Blancho G; Vanhove B
Immunotherapy; 2010 Sep; 2(5):625-36. PubMed ID: 20874646
[TBL] [Abstract][Full Text] [Related]
2. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
3. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: Belatacept, Bristol-Myers Squibb.
Vanhove B; Soulillou JP
Curr Opin Mol Ther; 2005 Aug; 7(4):384-93. PubMed ID: 16121705
[TBL] [Abstract][Full Text] [Related]
5. Co-signals in organ transplantation.
Durrbach A; Francois H; Jacquet A; Beaudreuil S; Charpentier B
Curr Opin Organ Transplant; 2010 Aug; 15(4):474-80. PubMed ID: 20631615
[TBL] [Abstract][Full Text] [Related]
6. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.
Bernett MJ; Chu SY; Leung I; Moore GL; Lee SH; Pong E; Chen H; Phung S; Muchhal US; Horton HM; Lazar GA; Desjarlais JR; Szymkowski DE
MAbs; 2013; 5(3):384-96. PubMed ID: 23549103
[TBL] [Abstract][Full Text] [Related]
7. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation.
Wojciechowski D; Vincenti F
Semin Immunol; 2011 Jun; 23(3):157-64. PubMed ID: 21856169
[TBL] [Abstract][Full Text] [Related]
8. The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
Oshima S; Karrer EE; Kawato Y; Maeda M; Fukahori H; Tsujimoto S; Hirose J; Nakamura K; Marui T; Takamura F; Noto T; Chapin SJ; Fujii Y; Neighbors M; Viswanathan S; Devens BH; Higashi Y
Transplantation; 2016 Dec; 100(12):2611-2620. PubMed ID: 27861289
[TBL] [Abstract][Full Text] [Related]
9. Belatacept: a new era of immunosuppression?
El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
[TBL] [Abstract][Full Text] [Related]
10. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
11. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
12. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk.
Bestard O; Campistol JM; Morales JM; Sánchez-Fructuoso A; Cabello M; Cabello V; Pallardó LM; Grinyó JM
Nefrologia; 2012 May; 32(3):374-84. PubMed ID: 22535159
[TBL] [Abstract][Full Text] [Related]
13. Costimulation targeting therapies in organ transplantation.
Gandhi AM; Fazli U; Rodina V; Qazi YA
Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
[TBL] [Abstract][Full Text] [Related]
14. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
15. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Riella LV; Sayegh MH
Expert Opin Biol Ther; 2013 Nov; 13(11):1557-68. PubMed ID: 24083381
[TBL] [Abstract][Full Text] [Related]
16. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
[TBL] [Abstract][Full Text] [Related]
17. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
[TBL] [Abstract][Full Text] [Related]
18. Decreased frequency of peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term therapy with Belatacept.
Vondran FW; Timrott K; Kollrich S; Klempnauer J; Schwinzer R; Becker T
Transpl Int; 2012 Apr; 25(4):455-63. PubMed ID: 22348376
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance.
Bahri R; Naji A; Menier C; Charpentier B; Carosella ED; Rouas-Freiss N; Durrbach A
J Immunol; 2009 Dec; 183(11):7054-62. PubMed ID: 19915057
[TBL] [Abstract][Full Text] [Related]
20. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]